<DOC>
	<DOCNO>NCT01003106</DOCNO>
	<brief_summary>The primary Objective study evaluate safety tolerability intraocular injection 0.5mg 2.0mg ranibizumab patient macular edema due retinal vein occlusion .</brief_summary>
	<brief_title>Ranibizumab DosE Comparison Role LAser REtinal Vein Occlusions</brief_title>
	<detailed_description>The secondary objective assess efficacy 0.5mg versus 2.0mg monthly ranibizumab injection patient macular edema due retinal vein occlusion baseline month 6 . At week 24 , patient re-randomized receive pro nata ( prn ) ranibizumab+laser photocoagulation versus ranibizumab alone efficacy treatment option compare . Treatment efficacy assess compare change best correct visual acuity ( BCVA ) central subfiled thickness ( CST ) treatment group .</detailed_description>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Signed informed consent authorization use disclosure protect health information Age equal great 18 year Diagnosis macular edema due central branch retinal vein occlusion Foveal thickness equal great 250 mm , assess OCT Best correct visual acuity score study eye 20/40 20/400 inclusive ( Snellen equivalent use ETDRS protocol distance 4 meter ) . Only one eye treat study . If eye eligible , investigator select eye enrol . In opinion investigator , decrease vision study eye due foveal thicken vein occlusion obvious cause decrease vision Scatter laser photocoagulation macular photocoagulation within 3 month study entry study eye Intraocular surgery study eye within 3 month study entry Use intraocular periocular injection steroid study eye ( e.g. , triamcinolone ) within 4 month study entry Previous use antiVEGF drug within 3 month study entry Cataract surgery study eye within 3 month study entry ; YttriumAluminumGarnet ( YAG ) laser capsulotomy within 1 month study entry ; intraocular surgery within 3 month precede Day 0 . History vitreoretinal surgery study eye within 3 month study entry Uncontrolled glaucoma ( defined intraocular pressure Â³30 mm Hg despite treatment antiglaucoma medication ) History cerebral vascular accident , myocardial infarction , transient ischemic attack within 3 month study enrollment . Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch . Have presence active malignancy , include lymphoproliferative disorder . Subjects history fully resolve basal squamous cell skin cancer may enrol . Any condition investigator believe would pose significant hazard subject investigational therapy initiate . History allergy humanize antibody component ranibizumab formulation Inability comply study followup procedure Participation another simultaneous medical investigation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>RVO</keyword>
	<keyword>BRVO</keyword>
	<keyword>CRVO</keyword>
	<keyword>Vein occlusion</keyword>
</DOC>